Effect of Cannabidiol (CBD) on Vision and Driving

March 20, 2024 updated by: Sonia Ortiz Peregrina, Universidad de Granada

Effect of Cannabidiol (CBD) Consumption on Visual Function and Driving Performance

The use of cannabis with ∆9-tetrahydrocannabinol (THC) content has been shown to have negative effects on vision and driving. The use of other cannabinoids, such as cannabidiol (CBD), which is not attributed with a psychoactive effect, is increasing significantly. This project aims to investigate whether consuming CBD can negatively affect visual function by assessing a wide range of visual parameters and whether these changes may pose a risk for everyday activities such as driving.

Study Overview

Status

Active, not recruiting

Conditions

Study Type

Interventional

Enrollment (Estimated)

60

Phase

  • Early Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Granada, Spain, 18071
        • University of Granada

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Being an occasional cannabis and/or cannabidiol user
  • Have a current driving licence
  • Have at least one year's driving experience
  • Drive at least once a week
  • Monocular visual acuity of at least 6/6 (Snellen) with habitual correction for driving
  • Absence of binocular disorders

Exclusion criteria:

  • Certain past or present medical conditions
  • Current cannabis or alcohol use disorder
  • Use of other drugs
  • Pregnancy or lactation
  • Simulator sickness.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Placebo (CBD 0%)
Participants are required to vaporize a placebo at 0% CBD concentration
Participants are required to vaporize placebo at 0% CBD concentration
Experimental: CBD 15%
Participants are required to vaporize CBD at a concentration of 15%.
Participants are required to vaporize CBD at a concentration of 15%.
Experimental: CBD 30%
Participants are required to vaporize CBD at a concentration of 30%.
Participants are required to vaporize CBD at a concentration of 30%.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Overall Driving Performance Score (ODPS) after cannabidiol vaporization
Time Frame: Participants are assessed 20 minutes after vaporization
To obtain the ODPS, Z-scores were calculated from individual parameters such as the standard deviation of the lateral lane position or the distance travelled into the opposite lane. The z-score is defined as a measure of how many standard deviations an individual value is below or above the group mean. The average Z-score of the individual driving variables is called the ODPS.
Participants are assessed 20 minutes after vaporization
Change in motion detection sensitivity after cannabidiol vaporization
Time Frame: Participants are assessed 20 minutes after vaporization
The subject has to indicate the direction of movement of a pattern of moving dots. The percentage of correct answers is obtained for different degrees of coherence.
Participants are assessed 20 minutes after vaporization
Change in contrast sensitivity after cannabidiol vaporization
Time Frame: Participants are assessed 20 minutes after vaporization
Contrast thresholds are obtained for different spatial frequencies
Participants are assessed 20 minutes after vaporization
Change in visual acuity after cannabidiol vaporization
Time Frame: Participants are assessed 20 minutes after vaporization
Visual acuity is assessed with a commercial test for distance vision.
Participants are assessed 20 minutes after vaporization
Change in fixations after cannabidiol vaporization
Time Frame: Participants are assessed 20 minutes after vaporization
The number of fixations made on different stimuli of interest in a task environment is counted using an eye tracker system.
Participants are assessed 20 minutes after vaporization

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Driving simulator: standard deviation of the lateral lane position (SDLP)
Time Frame: Participants are assessed 20 minutes after vaporization
Participants are assessed 20 minutes after vaporization
Distance travelled outside the lane
Time Frame: Participants are assessed 20 minutes after vaporization
The SDLP assesses the lane weaving that the subject performs in the lane and indicates whether the vehicle's position is consistent.
Participants are assessed 20 minutes after vaporization
Mean speed
Time Frame: Participants are assessed 20 minutes after vaporization
Average speed is obtained and analyzed in relation to the speed limits for different sections.
Participants are assessed 20 minutes after vaporization
Angular velocity of the steering wheel
Time Frame: Participants are assessed 20 minutes after vaporization
The angular velocity of the steering wheel is a metric that indicates the subject's ability to maintain the vehicle's position.
Participants are assessed 20 minutes after vaporization

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 1, 2023

Primary Completion (Actual)

September 30, 2023

Study Completion (Estimated)

December 31, 2025

Study Registration Dates

First Submitted

February 29, 2024

First Submitted That Met QC Criteria

March 13, 2024

First Posted (Actual)

March 21, 2024

Study Record Updates

Last Update Posted (Actual)

March 22, 2024

Last Update Submitted That Met QC Criteria

March 20, 2024

Last Verified

March 1, 2024

More Information

Terms related to this study

Other Study ID Numbers

  • C-EXP-194-UGR23

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cannabis Use

Clinical Trials on Placebo (CBD 0%)

3
Subscribe